EPCT-18. PHASE 0/I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA

BACKGROUND: Posterior fossa ependymoma (PF EPN) is a pediatric central nervous system malignancy that has a poor outcome to standard therapeutic approaches. The majority of PF EPN tumors have increased HER2 expression. Trastuzumab is a monoclonal antibody that targets HER2, and sargramostim (GM-CSF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorris, Kathleen, Widener, Melissa, Amani, Vladimir, Donson, Andrew, Schissel, Debra, Carson, Jessica, Mettetal, Ashley, Ramirez, Dominique, Gustafson, Daniel, Hankinson, Todd, Handler, Michael, Macy, Margaret, Foreman, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715093/
http://dx.doi.org/10.1093/neuonc/noaa222.140

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715093/
http://dx.doi.org/10.1093/neuonc/noaa222.140

Ejemplares similares